Efficacy and Tolerability of Pegloticase for the Treatment of Chronic Gout in Patients Refractory to Conventional Treatment

医学 痛风 内科学 耐受性 耐火材料(行星科学) 不利影响 物理 天体生物学
作者
John S. Sundy,Herbert S. B. Baraf,Robert A. Yood,N. Lawrence Edwards,Sergio Gutiérrez‐Ureña,Edward L. Treadwell,Janitzia Vázquez-Mellado,William B. White,Peter E. Lipsky,Zeb Horowitz,William J. Huang,Allan N. Maroli,Royce W. Waltrip,Steven A. Hamburger,Michael A. Becker
出处
期刊:JAMA [American Medical Association]
卷期号:306 (7): 711-711 被引量:483
标识
DOI:10.1001/jama.2011.1169
摘要

Patients with chronic disabling gout refractory to conventional urate-lowering therapy need timely treatment to control disease manifestations related to tissue urate crystal deposition. Pegloticase, monomethoxypoly(ethylene glycol)-conjugated mammalian recombinant uricase, was developed to fulfill this need.To assess the efficacy and tolerability of pegloticase in managing refractory chronic gout.Two replicate, randomized, double-blind, placebo-controlled trials (C0405 and C0406) were conducted between June 2006 and October 2007 at 56 rheumatology practices in the United States, Canada, and Mexico in patients with severe gout, allopurinol intolerance or refractoriness, and serum uric acid concentration of 8.0 mg/dL or greater. A total of 225 patients participated: 109 in trial C0405 and 116 in trial C0406.Twelve biweekly intravenous infusions containing either pegloticase 8 mg at each infusion (biweekly treatment group), pegloticase alternating with placebo at successive infusions (monthly treatment group), or placebo (placebo group).Primary end point was plasma uric acid levels of less than 6.0 mg/dL in months 3 and 6.In trial C0405 the primary end point was reached in 20 of 43 patients in the biweekly group (47%; 95% CI, 31%-62%), 8 of 41 patients in the monthly group (20%; 95% CI, 9%-35%), and in 0 patients treated with placebo (0/20; 95% CI, 0%-17%; P < .001 and <.04 for comparisons between biweekly and monthly groups vs placebo, respectively). Among patients treated with pegloticase in trial C0406, 16 of 42 in the biweekly group (38%; 95% CI, 24%-54%) and 21 of 43 in the monthly group (49%; 95% CI, 33%-65%) achieved the primary end point; no placebo-treated patients reached the primary end point (0/23; 95% CI, 0%-15%; P = .001 and < .001, respectively). When data in the 2 trials were pooled, the primary end point was achieved in 36 of 85 patients in the biweekly group (42%; 95% CI, 32%-54%), 29 of 84 patients in the monthly group (35%; 95% CI, 24%-46%), and 0 of 43 patients in the placebo group (0%; 95% CI, 0%-8%; P < .001 for each comparison). Seven deaths (4 in patients receiving pegloticase and 3 in the placebo group) occurred between randomization and closure of the study database (February 15, 2008).Among patients with chronic gout, elevated serum uric acid level, and allopurinol intolerance or refractoriness, the use of pegloticase 8 mg either every 2 weeks or every 4 weeks for 6 months resulted in lower uric acid levels compared with placebo.clinicaltrials.gov Identifier: NCT00325195.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
Cml发布了新的文献求助30
1秒前
河大谢广坤完成签到,获得积分10
1秒前
2秒前
3秒前
111111发布了新的文献求助10
3秒前
6秒前
陌予发布了新的文献求助10
7秒前
8秒前
缓慢的开山完成签到 ,获得积分10
10秒前
11秒前
量子星尘发布了新的文献求助10
13秒前
ash完成签到,获得积分20
15秒前
15秒前
16秒前
英俊的铭应助月月采纳,获得10
19秒前
ash发布了新的文献求助100
19秒前
周也发布了新的文献求助10
19秒前
文献菜鸟完成签到 ,获得积分10
20秒前
淅淅12345完成签到,获得积分20
20秒前
小二郎应助zhan采纳,获得10
20秒前
23秒前
23秒前
osmanthus完成签到,获得积分10
23秒前
feng1235完成签到,获得积分10
25秒前
拓木幸子完成签到,获得积分10
26秒前
热心市民小红花应助陈昊采纳,获得10
26秒前
27秒前
lcr发布了新的文献求助10
28秒前
Ginkgo完成签到 ,获得积分10
29秒前
安静海露完成签到,获得积分10
29秒前
30秒前
zhan完成签到,获得积分10
31秒前
顾矜应助anna采纳,获得10
31秒前
朴素的士晋完成签到 ,获得积分10
31秒前
33秒前
思源应助YJ888采纳,获得10
33秒前
安静海露发布了新的文献求助10
34秒前
售后延长完成签到 ,获得积分10
35秒前
传奇3应助Cml采纳,获得10
36秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989069
求助须知:如何正确求助?哪些是违规求助? 3531351
关于积分的说明 11253589
捐赠科研通 3269939
什么是DOI,文献DOI怎么找? 1804851
邀请新用户注册赠送积分活动 882074
科研通“疑难数据库(出版商)”最低求助积分说明 809073